Boone Capital Management liquidated its entire $13.57 million stake in Cogent Biosciences (945,042 shares) in Q4 2026, despite the stock surging 372% over the past year. The fund reallocated capital to earlier-stage biotech opportunities like TYRA, which has gained 40% in 2026, suggesting a strategic shift toward higher-risk, higher-upside clinical-stage investments.

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

Mirum Pharmaceuticals showed profitability in Q3 2025 and strong revenue growth of 56.8% year-over-year through nine months. However, the company faces headwinds including slowing sales growth guidance for 2026 (23.1% vs 54.4% in 2025) and near-term profitability challenges from the $620 million Bluejay Therapeutics acquisition. While the stock has doubled over 12 months, analysts suggest profitability may take several more years to achieve consistently.

Eventide Asset Management sold 114,922 shares of Mirum Pharmaceuticals in Q3, but the position's value increased by approximately $50.70 million to $184.92 million due to the stock's 89% surge over the past year. The share reduction appears to be portfolio management rather than a loss of confidence, as Mirum posted strong Q3 revenue growth of 47% and raised full-year guidance, with the company now representing the fund's second-largest equity holding.

Mirum Pharmaceuticals has seen nearly 70% stock growth in 2025, with its flagship drug Livmarli driving sales and potential for continued expansion in 2026, supported by promising pipeline candidates volixibat and MRM-3379.

Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.

Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further. However, overdependence on Livmarli for revenues is a concern.

Mirum's (MIRM) earnings and revenues miss estimates in the first quarter of 2024. Livmarli drives year-over-year sales.

In the preceding three months, 10 analysts have released ratings for Mirum Pharmaceuticals (NASDAQ:MIRM), presenting a wide array of perspectives from bullish to bearish. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 5 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 1 3 0 0 0 Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $52.6, a high estimate of $72.00, and a low estimate of $35.00. This current average represents a 1.29% decrease from the previous average price target of $53.29. Investigating Analyst Ratings: An Elaborate Study A comprehensive examination of how financial experts perceive Mirum Pharmaceuticals is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Ed Arce HC Wainwright & Co. Maintains Buy $58.00 - Dae Gon Ha Stifel Announces Buy $48.00 - Ed Arce HC Wainwright & Co. Maintains Buy $58.00 $58.00 Mani Foroohar Leerink Partners Lowers Outperform $43.00 $44.00 Jonathan Wolleben JMP Securities Raises Outperform $72.00 $69.00 Ed Arce HC Wainwright & Co. Raises Buy $58.00 $45.00 Josh Schimmer Cantor Fitzgerald Raises Overweight $40.00 $35.00 Ed Arce HC Wainwright & Co. Lowers Buy $45.00 $58.00 Jonathan Wolleben JMP Securities Raises Market Outperform $69.00 $64.00 Josh Schimmer Cantor Fitzgerald Maintains Overweight $35.00 - Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to ...Full story available on Benzinga.com

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.